Skip to Main Content

++

Chapter 61. Glaucoma

++
++
++

The preferred treatment option for a 67-year-old man with primary open-angle glaucoma (POAG), no significant past medical history (PMH), and allergy to benzalkonium chloride is:

++
++
++

A. Tafluprost

++
++

B. Latanoprost

++
++

C. Brinzolamide

++
++

D. Carbachol

++
++

E. Levobunolol

++
++
++

An appropriate counseling statements for timolol is:

++
++
++

A. This medication has no significant systemic effects.

++
++

B. This medication may cause mydriasis.

++
++

C. Do not use this medication if you are allergic to sulfonamides.

++
++

D. This medication may cause an increase in iris pigmentation.

++
++

E. This medication may cause bradycardia.

++
++
++

All of the following characteristics would increase a patient’s risk of developing primary angle-closure glaucoma except:

++
++
++

A. Myopia

++
++

B. Female gender

++
++

C. Shallow anterior chamber

++
++

D. Central corneal thickness of 560 μm

++
++

E. Asian descent

++
++
++

The following drug would be contraindicated in a patient with with primary open-angle glaucoma (POAG) and allergy to sulfonamides:

++
++
++

A. Travoprost

++
++

B. Betaxolol

++
++

C. Brinzolamide

++
++

D. Pilocarpine

++
++
++

The following drug has little clinically significant systemic adverse effects:

++
++
++

A. Bimatoprost

++
++

B. Brimonidine

++
++

C. Carteolol

++
++

D. Acetazolamide

++
++

E. Apraclonidine

++
++
++

The following drug may darken pigmentation of the iris:

++
++
++

A. Tafluprost

++
++

B. Carteolol

++
++

C. Brinzolamide

++
++

D. Pilocarpine

++
++

E. Levobunolol

++
++
++

The following medications are likely to increase IOP in a patient with primary angle-closure glaucoma (PACG) except:

++
++
++

A. Diphenhydramine

++
++

B. Amitriptyline

++
++

C. Pseudoephedrine

++
++

D. Lisinopril

...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.